KOSDAQBiotech & Pharma110020

Jeonjinbio

₩2,005▼ 0.50%2026-11-18 close
Market Cap
₩18.2B
Turnover
₩3,348,851
Volume
1.7K
Shares out.
9.1M
PER
—
PBR
1.1×
EPS
-₩108
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Can home-care expansion break the loss streak?

Jeonjinbio, a capsule-detergent ODM maker, swung back to an operating loss in 2025 after its 2024 profit and has posted losses for four straight quarters through the third quarter of 2026. The home-care automation line and the 2027 revenue target are the next checkpoints.

  1. 1

    Operating profit of KRW 1.16 billion in 2024 turned into an operating loss of KRW 343 million in 2025, and losses have continued for four straight quarters since the fourth quarter of 2025.

  2. 2

    First-half 2026 revenue was KRW 5.822 billion, slightly up year on year, while the operating loss widened to KRW 460 million.

  3. 3

    A home-care automation line built with about KRW 1 billion was reported to start commercial operation in the fourth quarter of 2026, with estimated annual supply capacity above KRW 5 billion.

  4. 4

    The 2027 revenue target is well above the KRW 13.7 billion disclosed for 2025.

  5. 5

    Total liabilities were KRW 1.1 billion and the debt ratio was 6.3% at the end of 2025, so the financial burden is low, while the operating margin of -2.5% in 2025 leaves profitability recovery as the central task.

02

Business structure

Jeonjinbio started with a pest-damage reduction business built on a natural-material library and has widened into household and animal products. Its core item is the capsule-type laundry detergent, and it is positioned as a differentiated brand in the household market.

In the first half of 2026, the revenue mix was 77.3% household products, 18.6% animal products and 4.0% pest-damage reduction agents. First-half revenue was KRW 5.822 billion according to the semi-annual report, of which household products accounted for KRW 4.499 billion.

Capsule detergent, including domestic and export sales, reached KRW 3.617 billion, or 62.1% of the total. The company has ODM capability covering product planning through manufacturing and packaging, and it listed on KOSDAQ in 2018.

Because production follows the orders of client brands, the client mix is a key driver of revenue swings. Customer diversification is progressing, with Yuhan expanding a premium product line, Atomy diversifying supplied items, and a military welfare agency adding supply categories.

Export sales of capsule detergent reached KRW 859 million in the first half of 2026, above the full-year 2025 export figure of KRW 788 million. The company plans to broaden distribution channels for pet food to diversify revenue.

Because it works as a contract producer rather than selling under its own brand, its sales depend on client ordering decisions. Yuhan, which is in the same biopharma sector, also appears as a client.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩4.5B₩300M7.3%
2025Q4₩3.4B-₩300M−8.1%
2026Q1₩2.9B-₩200M−6.9%
2026Q2₩2.9B-₩300M−8.9%
2026Q3₩3.4B-₩300M−9.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩7.8B-₩3.2B-₩3.2B−40.8%−33.2%87.9%
2023₩15.7B-₩1.2B-₩6.4B−7.9%−103.5%184.6%
2024₩19.3B₩1.2B₩4.3B6.0%24.6%6.7%
2025₩13.7B-₩300M-₩200M−2.5%−1.1%6.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On an annual basis, revenue rose from KRW 7.79 billion in 2022 to KRW 15.7 billion in 2023 (up 101.2% year on year) and KRW 19.3 billion in 2024 (up 22.9%), then fell to KRW 13.7 billion in 2025 (down 28.9%). Among 2022 to 2025, 2024 was the largest year and 2022 the smallest.

The operating loss of KRW 3.18 billion in 2022 narrowed to KRW 1.24 billion in 2023, and the company returned to operating profit of KRW 1.16 billion in 2024. In 2025 it swung back to an operating loss of KRW 343 million. Operating margin moved from -40.8% in 2022 to -7.9% in 2023, 6.0% in 2024 and -2.5% in 2025.

Net income attributable to controlling shareholders turned from a loss of KRW 6.44 billion in 2023 to a profit of KRW 4.35 billion in 2024, then a loss of KRW 196 million in 2025. Net income including non-controlling interests moved in the same direction in those years.

Operating cash flow was negative in 2022 and 2023, turned positive at KRW 3.01 billion in 2024 and was KRW 483 million in 2025. The debt ratio fell from 87.9% in 2022 and 184.6% in 2023 to 6.7% in 2024 and 6.3% in 2025.

Quarterly revenue peaked at KRW 4.45 billion in the third quarter of 2025, then dropped to KRW 3.44 billion in the fourth quarter (down 22.8% quarter on quarter) and KRW 2.88 billion in the first quarter of 2026 (down 16.1%).

It then rose to KRW 2.94 billion in the second quarter and KRW 3.43 billion in the third quarter, two consecutive quarterly gains, though third-quarter revenue was still down 23.1% year on year.

Operating results moved from a profit of KRW 326 million in the third quarter of 2025 to losses in each of the four quarters that followed, with the loss narrowing in the first quarter of 2026 and widening in the second and third quarters.

Net loss attributable to controlling shareholders over the last four quarters totaled KRW 970 million. First-half 2026 gross margin was 22.2%, below 25.8% a year earlier, and the first-half operating loss of KRW 460 million matches the sum of the disclosed first- and second-quarter losses.

An outside research firm attributed the cost pressure to supply disruptions of raw and sub-materials linked to geopolitical risk, and called it a temporary burden. That is an analyst estimate rather than a company disclosure, and no one-off items were identified in the disclosed figures.

05

Industry analysis

Jeonjinbio is classified under the KOSDAQ chemicals sector and, under the WI26 scheme, as a consumer staple. Its business differs from pharmaceuticals, but Yuhan, a company in the same biopharma sector, is one of its clients.

Capsule-detergent OEM and ODM volumes are set by the product planning and distribution strategies of brand owners. An outside research firm said the company's ODM competitiveness and the expansion into new home-care categories remained intact.

The company highlights an ODM process running from formulation through filling and packaging. On that base it plans to widen its product list with capsules for dishwashers and new home-care products.

Supply of raw and sub-materials is a key variable for production, and an outside analysis linked the first-half 2026 disruption to geopolitical risk. The company is raising line utilization on its automated production lines and pursuing lower manufacturing cost ratios as volumes grow.

Export demand is also gaining weight, as capsule-detergent exports in the first half of 2026 exceeded the full-year 2025 export figure. By contrast, the lower first-half gross margin signals higher cost pressure, so volume growth and cost control need to progress together.

Direct comparison of scale with listed peers is limited by differences in business structure, so industry resilience is best read through the client mix and cost management.

06

Outlook

The company has set a 2027 annual revenue target of KRW 20.73 billion, well above the KRW 13.7 billion disclosed for 2025, so the path to that target is the main item to watch.

The core lever is a home-care automation line built at a cost of about KRW 1 billion, which was reported to begin commercial operation in the fourth quarter of 2026.

The supply capacity secured by the new line is estimated at more than KRW 5 billion a year, which is more than one-third of the 2025 revenue of KRW 13.7 billion.

An analyst said the expansion responds to home-care demand that clients confirmed in advance, and expected the effect to show more clearly in 2027 results than in 2026. The wider supply list is also expected to reduce the impact of order swings from any single client.

On the margin side, the question is whether higher line utilization and lower manufacturing cost ratios translate into a recovery in operating margin. The pet-food channel expansion will show how far the 18.6% animal-products share can grow.

Renewed supply disruption of raw and sub-materials could offset the line's benefit. The next step is to track in the disclosures how quarterly revenue and operating losses change after the line starts.

07

Valuation

PER
—
PBR
1.1×
ROE
-5.6%
EPS
-₩108
BPS
₩1,876
Dividend per share
₩0

Because the company has posted net losses attributable to controlling shareholders over the last four quarters, an earnings-based multiple cannot be calculated. The price-to-book ratio sits near book value, with no large premium over net assets.

Equity of KRW 17.4 billion at the end of 2025 is entirely attributable to controlling shareholders, and total liabilities of KRW 1.1 billion leave the valuation more dependent on asset value. On FnGuide data, EV/EBITDA runs well above the average of the KOSDAQ chemicals sector.

A small EBITDA base is one reason the multiple looks inflated. The dividend yield is below the sector average. The same share price means different things in 2024, when operating profit was positive, than in the loss-making years from 2025.

If quarterly profits return to the black, earnings-based multiples can be calculated again, which makes the earnings recovery the starting point for any multiple comparison.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Evidence of a 2024 turnaround

The company moved from an operating loss of KRW 3.18 billion in 2022 to operating profit of KRW 1.16 billion in 2024, with a 6.0% operating margin that year. Losses returned in 2025, but quarterly revenue has risen for two straight quarters since the first-quarter low in 2026. That the business earned an operating profit once is the core support for the bull case.

Home-care line and client diversification

A home-care automation line built with about KRW 1 billion was reported to start in the fourth quarter of 2026, with estimated annual supply above KRW 5 billion. The research firm said the expansion matches demand that clients confirmed in advance. Wider supply categories across Yuhan, Atomy and a military welfare agency were cited as positives.

Low debt and positive operating cash flow

Total liabilities were KRW 1.1 billion and the debt ratio was 6.3% at the end of 2025. Equity of KRW 17.4 billion is wholly attributable to controlling shareholders, which keeps borrowing burden small.

Operating cash flow stayed positive at KRW 3.01 billion in 2024 and KRW 483 million in 2025, giving financial buffer even during the loss years.

09

Bear factors

Four straight quarters of operating losses

The third-quarter loss of KRW 328 million turned from a year-earlier profit. First-half 2026 gross margin of 22.2% was below the 25.8% of a year earlier. The failure of losses to keep narrowing is the central bear point.

Revenue recovery not matched by narrower losses

Third-quarter 2026 revenue rose 16.7% from the prior quarter but was 23.1% below a year earlier. Even as revenue grew, operating losses widened in the second and third quarters. The bear reading is that the pace of sales recovery has not carried through to profitability.

External shocks and cost pressure

An outside research firm estimated that supply disruptions of raw and sub-materials tied to geopolitical risk affected production and supply, and called it temporary. If external factors persist, cost structure improvement may be slow. The lower first-half gross margin can also be read as a sign that cost pressure remains.

10

Risk factors

Raw and sub-material supply risk

If geopolitical tensions disrupt raw and sub-material supply, production and delivery are constrained. The disruption was cited as one reason the first-half 2026 operating loss widened. Even with more automated capacity, expansion benefits could be offset if sourcing stays unstable. Quarterly results are the practical way to track the effect.

Client and product concentration

Household products made up 77.3% of first-half 2026 revenue, a heavy concentration in one segment. Under an ODM model, order changes from major clients flow straight into revenue. Client supply lists are expanding, but the revenue share of each client is not fully visible in the disclosures. Whether new client wins show up in revenue scale is the open question.

Delayed realization of the expansion

The home-care line was reported to start in the fourth quarter of 2026, but if utilization rises slowly, the KRW 20.73 billion 2027 revenue target may be hard to reach. The company itself is pursuing higher line utilization to lower its manufacturing cost ratio. If volumes do not grow, fixed-cost burden could widen losses.

11

What to watch next

  1. By late December 2026

    Check the commercial operating status and utilization of the home-care automation line. Whether it lifts quarterly revenue and narrows losses is the first signal.

  2. By March 31, 2027

    The 2026 annual report will disclose full-year revenue and operating results. It is the baseline against the 2027 revenue target of KRW 20.73 billion.

  3. By May 15, 2027

    The first-quarter 2027 report will show whether the line's effect is visible and whether gross margin recovers from 22.2% in the first half of 2026.

12

Overall view

Jeonjinbio is a household-products maker built around capsule-detergent ODM. After a 2024 return to profit, it swung to a loss in 2025 and has posted operating losses for four straight quarters through the third quarter of 2026.

Quarterly revenue has risen for two straight quarters since the first-quarter low, but operating losses widened again in the second and third quarters. The balance sheet is light, with total liabilities of KRW 1.1 billion and a 6.3% debt ratio, and operating cash flow was positive in 2024 and 2025.

Growth levers include the home-care automation line built at about KRW 1 billion, a broader client base and new items such as dishwasher capsules. On the other side, raw-material supply disruption and the lower first-half gross margin remain unresolved weaknesses.

The 2027 revenue target of KRW 20.73 billion is well above the 2025 disclosed revenue, so how it is achieved is the main item to watch. The next checkpoints are the line's operation in late 2026, the 2026 annual report due by March 31, 2027, and the first-quarter 2027 report due by May 15, 2027. This report is for information only and contains no investment opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 11 more articles and sources
  1. m.news.nate.com
  2. newstopkorea.com
  3. comp.fnguide.com
  4. investing.com
  5. newspim.com
  6. comp.wisereport.co.kr
  7. goinsider.kr
  8. comp.fnguide.com
  9. the-stock.kr
  10. the-stock.kr
  11. alpha-lenz.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis